Cargando…
Personalized medicine and allergen immunotherapy: the beginning of a new era?
The concept of personalized medicine as a diagnostic and therapeutic approach tailored to the medical needs of each patient is currently revolutionizing all fields of medicine and in particular allergology. Allergen immunotherapy (AIT) meets the three main needs for precision medicine: identificatio...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262025/ https://www.ncbi.nlm.nih.gov/pubmed/34233706 http://dx.doi.org/10.1186/s12948-021-00150-z |
_version_ | 1783719115113889792 |
---|---|
author | Incorvaia, Cristoforo Ridolo, Erminia Bagnasco, Diego Scurati, Silvia Canonica, Giorgio Walter |
author_facet | Incorvaia, Cristoforo Ridolo, Erminia Bagnasco, Diego Scurati, Silvia Canonica, Giorgio Walter |
author_sort | Incorvaia, Cristoforo |
collection | PubMed |
description | The concept of personalized medicine as a diagnostic and therapeutic approach tailored to the medical needs of each patient is currently revolutionizing all fields of medicine and in particular allergology. Allergen immunotherapy (AIT) meets the three main needs for precision medicine: identification of molecular mechanism of disease, diagnostic tools for the mechanism and treatment blocking the mechanism itself. AIT adapts to the spectrum of specific IgE of each individual subject, changing the course and natural history of the disease, so is a clear model of precision and personalized medicine. This first step before the prescription of AIT is to define the sensitization profile of the patient; after that, the healthcare professional has numerous levers for adapting the treatment to the physio-pathological mechanisms involved. AIT allows to adapt treatments to the profile of the patients, but also to the its preferences, to ensure optimal treatment efficacy, resulting in an agile and personalized approach, with the aim to ensure adherence to the treatment, which is usually quite low. AIT also broadens the field of possibilities for healthcare professionals and patients, by allowing to choose the galenic formulation according to patient preferences and on the basis of their clinical history, adapting the product composition to the patient’s sensitization profiles and the underlying biological mechanisms identified at the diagnostic stage, while guaranteeing quality of the prescribed product as the production of allergens and allergoids is today more regulated than in the past years. In the management of AIT, it is also possible to involve patients in decisions throughout their care pathway thanks to multiple services, offering personalized follow-up and support, to ensure the highest treatment efficacy levels, and recalling medication intake, medical appointments and prescription renewals. |
format | Online Article Text |
id | pubmed-8262025 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-82620252021-07-08 Personalized medicine and allergen immunotherapy: the beginning of a new era? Incorvaia, Cristoforo Ridolo, Erminia Bagnasco, Diego Scurati, Silvia Canonica, Giorgio Walter Clin Mol Allergy Commentary The concept of personalized medicine as a diagnostic and therapeutic approach tailored to the medical needs of each patient is currently revolutionizing all fields of medicine and in particular allergology. Allergen immunotherapy (AIT) meets the three main needs for precision medicine: identification of molecular mechanism of disease, diagnostic tools for the mechanism and treatment blocking the mechanism itself. AIT adapts to the spectrum of specific IgE of each individual subject, changing the course and natural history of the disease, so is a clear model of precision and personalized medicine. This first step before the prescription of AIT is to define the sensitization profile of the patient; after that, the healthcare professional has numerous levers for adapting the treatment to the physio-pathological mechanisms involved. AIT allows to adapt treatments to the profile of the patients, but also to the its preferences, to ensure optimal treatment efficacy, resulting in an agile and personalized approach, with the aim to ensure adherence to the treatment, which is usually quite low. AIT also broadens the field of possibilities for healthcare professionals and patients, by allowing to choose the galenic formulation according to patient preferences and on the basis of their clinical history, adapting the product composition to the patient’s sensitization profiles and the underlying biological mechanisms identified at the diagnostic stage, while guaranteeing quality of the prescribed product as the production of allergens and allergoids is today more regulated than in the past years. In the management of AIT, it is also possible to involve patients in decisions throughout their care pathway thanks to multiple services, offering personalized follow-up and support, to ensure the highest treatment efficacy levels, and recalling medication intake, medical appointments and prescription renewals. BioMed Central 2021-07-07 /pmc/articles/PMC8262025/ /pubmed/34233706 http://dx.doi.org/10.1186/s12948-021-00150-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Commentary Incorvaia, Cristoforo Ridolo, Erminia Bagnasco, Diego Scurati, Silvia Canonica, Giorgio Walter Personalized medicine and allergen immunotherapy: the beginning of a new era? |
title | Personalized medicine and allergen immunotherapy: the beginning of a new era? |
title_full | Personalized medicine and allergen immunotherapy: the beginning of a new era? |
title_fullStr | Personalized medicine and allergen immunotherapy: the beginning of a new era? |
title_full_unstemmed | Personalized medicine and allergen immunotherapy: the beginning of a new era? |
title_short | Personalized medicine and allergen immunotherapy: the beginning of a new era? |
title_sort | personalized medicine and allergen immunotherapy: the beginning of a new era? |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262025/ https://www.ncbi.nlm.nih.gov/pubmed/34233706 http://dx.doi.org/10.1186/s12948-021-00150-z |
work_keys_str_mv | AT incorvaiacristoforo personalizedmedicineandallergenimmunotherapythebeginningofanewera AT ridoloerminia personalizedmedicineandallergenimmunotherapythebeginningofanewera AT bagnascodiego personalizedmedicineandallergenimmunotherapythebeginningofanewera AT scuratisilvia personalizedmedicineandallergenimmunotherapythebeginningofanewera AT canonicagiorgiowalter personalizedmedicineandallergenimmunotherapythebeginningofanewera |